Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)

Bradley A. Schiff; Andrea B. McMurphy; Samar A. Jasser; Maher N. Youne; Dao Doan; Orhan G. Yigitbasi; Seungwon Kim; Ge Zhou; Mahitosh Mandal; Benjamin N. Bekele; FChristopher C. Holsinger; Steven I. Sherman; Sai Ching Yeung; Adel K. El-Naggar; Jeffrey N. Myers

doi:10.1158/1078-0432.CCR-19-2052

Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)

Bradley A. Schiff, Andrea B. McMurphy, Samar A. Jasser, Maher N. Youne, Dao Doan, Orhan G. Yigitbasi, Seungwon Kim, Ge Zhou, Mahitosh Mandal, Benjamin N. Bekele, FChristopher C. Holsinger, Steven I. Sherman, Sai Ching Yeung, Adel K. El-Naggar, Jeffrey N. Myers

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

The editors are publishing this note to alert readers to a concern about this article (1): In Fig. 2B, a splice line is missing in the NPA 187 lane of the b-actin panel.

Original language	English (US)
Pages (from-to)	4862
Number of pages	1
Journal	Clinical Cancer Research
Volume	25
Issue number	15
DOIs	https://doi.org/10.1158/1078-0432.CCR-19-2052
State	Published - Aug 1 2019

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-19-2052

Fingerprint

Dive into the research topics of 'Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)'. Together they form a unique fingerprint.

Cite this

Schiff, B. A., McMurphy, A. B., Jasser, S. A., Youne, M. N., Doan, D., Yigitbasi, O. G., Kim, S., Zhou, G., Mandal, M., Bekele, B. N., Holsinger, FC. C., Sherman, S. I., Yeung, S. C., El-Naggar, A. K., & Myers, J. N. (2019). Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690). Clinical Cancer Research, 25(15), 4862. https://doi.org/10.1158/1078-0432.CCR-19-2052

Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690). / Schiff, Bradley A.; McMurphy, Andrea B.; Jasser, Samar A. et al.
In: Clinical Cancer Research, Vol. 25, No. 15, 01.08.2019, p. 4862.

Research output: Contribution to journal › Comment/debate › peer-review

Schiff, BA, McMurphy, AB, Jasser, SA, Youne, MN, Doan, D, Yigitbasi, OG, Kim, S, Zhou, G, Mandal, M, Bekele, BN, Holsinger, FCC, Sherman, SI , Yeung, SC , El-Naggar, AK & Myers, JN 2019, 'Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)', Clinical Cancer Research, vol. 25, no. 15, pp. 4862. https://doi.org/10.1158/1078-0432.CCR-19-2052

Schiff BA, McMurphy AB, Jasser SA, Youne MN, Doan D, Yigitbasi OG et al. Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690). Clinical Cancer Research. 2019 Aug 1;25(15):4862. doi: 10.1158/1078-0432.CCR-19-2052

Schiff, Bradley A. ; McMurphy, Andrea B. ; Jasser, Samar A. et al. / Erratum : Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690). In: Clinical Cancer Research. 2019 ; Vol. 25, No. 15. pp. 4862.

@article{63d88168b94c451487162029e37a961e,

title = "Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)",

abstract = "The editors are publishing this note to alert readers to a concern about this article (1): In Fig. 2B, a splice line is missing in the NPA 187 lane of the b-actin panel.",

author = "Schiff, {Bradley A.} and McMurphy, {Andrea B.} and Jasser, {Samar A.} and Youne, {Maher N.} and Dao Doan and Yigitbasi, {Orhan G.} and Seungwon Kim and Ge Zhou and Mahitosh Mandal and Bekele, {Benjamin N.} and Holsinger, {FChristopher C.} and Sherman, {Steven I.} and Yeung, {Sai Ching} and El-Naggar, {Adel K.} and Myers, {Jeffrey N.}",

note = "Publisher Copyright: {\textcopyright}2019 American Association for Cancer Research.",

year = "2019",

month = aug,

day = "1",

doi = "10.1158/1078-0432.CCR-19-2052",

language = "English (US)",

volume = "25",

pages = "4862",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "15",

}

TY - JOUR

T1 - Erratum

T2 - Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)

AU - Schiff, Bradley A.

AU - McMurphy, Andrea B.

AU - Jasser, Samar A.

AU - Youne, Maher N.

AU - Doan, Dao

AU - Yigitbasi, Orhan G.

AU - Kim, Seungwon

AU - Zhou, Ge

AU - Mandal, Mahitosh

AU - Bekele, Benjamin N.

AU - Holsinger, FChristopher C.

AU - Sherman, Steven I.

AU - Yeung, Sai Ching

AU - El-Naggar, Adel K.

AU - Myers, Jeffrey N.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - The editors are publishing this note to alert readers to a concern about this article (1): In Fig. 2B, a splice line is missing in the NPA 187 lane of the b-actin panel.

AB - The editors are publishing this note to alert readers to a concern about this article (1): In Fig. 2B, a splice line is missing in the NPA 187 lane of the b-actin panel.

UR - http://www.scopus.com/inward/record.url?scp=85070086452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070086452&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-19-2052

DO - 10.1158/1078-0432.CCR-19-2052

M3 - Comment/debate

C2 - 31371312

AN - SCOPUS:85070086452

SN - 1078-0432

VL - 25

SP - 4862

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 15

ER -

Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this